Pfizer Inc. $PFE Shares Acquired by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 16.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 190,203 shares of the biopharmaceutical company’s stock after purchasing an additional 27,199 shares during the quarter. Sumitomo Mitsui Financial Group Inc.’s holdings in Pfizer were worth $4,736,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PFE. Horizon Financial Services LLC raised its position in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter worth about $26,000. YANKCOM Partnership bought a new stake in Pfizer in the fourth quarter worth about $28,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new stake in Pfizer in the second quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $26.17 on Friday. The stock’s 50-day moving average price is $26.48 and its two-hundred day moving average price is $26.32. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market cap of $149.15 billion, a PE ratio of 19.98 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded HYMPAVZI’s U.S. indication to include more hemophilia A and B patients, including pediatric use, improving Pfizer’s rare-disease growth outlook and potentially boosting future sales. Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI
• Positive Sentiment: RBC Capital Markets upgraded Pfizer to Sector Perform, saying the stock’s recent weakness has improved the risk-reward profile and reset valuation ahead of key pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Multiple articles highlighted Pfizer’s obesity, oncology, and pneumococcal pipeline updates, signaling continued investment in new growth drivers beyond COVID-era revenues. Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline
• Neutral Sentiment: Articles discussing Pfizer’s dividend yield and whether the stock is a buy or hold are mostly commentary, but they reinforce investor interest in PFE as an income name. A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
• Negative Sentiment: Pfizer’s CEO warned that planned investment in Germany could be reconsidered because of proposed drug-pricing changes, underscoring ongoing policy risk for the company. Pfizer CEO warns German investment at risk over drug pricing policies

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. Finally, Guggenheim boosted their price target on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.82.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.